We use non-essential cookies (including anonymous analytics) to help us understand if our website is working well and to learn what content is most useful to visitors. We also use some cookies which are essential for our platform to work and help us to provide you with the best experience possible. You can accept or reject our non-essential cookies and change your mind at any time. To learn more, please read our cookies policy.

Update cookie preferences

Ola Wlodek

Chief Operating Officer at Reflection Therapeutics



Ola Wlodek, a Chief Operating Officer at Reflection Therapeutics, has a PhD in mitochondrial biology from Cambridge University, and studies executive MBA at Warwick Business School. After her PhD, she spent five years at Isomerase Therapeutics, where she worked in a range of research roles, before co-founding Reflection Therapeutics, a Cambridge-based company developing a new cell therapy for amyotrophic lateral sclerosis.

Reason for joining the NGWC:

"I am incredibly excited to join the inaugural Ovarian Cancer Action Next Generation Women's Collective - especially at this difficult time for all the research charities. Through the NGWC initiative I am committed to raise funds for life-saving ovarian cancer research, alongside the other inspiring women of NGWC, and I am very grateful for this opportunity."

Contact details